CYRX Stock Cash Flow Statements

Cryoport Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Cryoport Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2012-12-31	2012-09-30	2012-06-30	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2008-12-31	2008-09-30	2008-06-30

cash flows from operating activities:
net income	-18,677,000	805,000	-77,989,000	-18,895,000	-62,389,000	-13,269,000	-18,355,000	-5,574,000	-9,436,000	-5,316,000	-9,177,000	-13,404,000	-260,086,000	-6,526,000	-5,389,000	-3,527,000	-11,529,540	-11,417,821	-5,802,746	-3,942,893	-947,539	-12,468,547	-2,528,491	-2,386,902	-2,258,264	-2,143,687	-2,470,890	-2,682,760	-1,979,664	-1,860,457	-1,789,211	-2,184,468	-3,934,714	-2,710,184	-2,760,453	-2,425,463	-1,924,264	-1,937,132	-1,407,758	-1,384,759	-2,297,264	-1,441,910	-1,840,331	-1,567,011	-1,552,704	-1,545,807	-2,030,110	-2,053,854	-1,857,017	-1,456,636	-1,509,821	-1,328,804		2,450,669	-7,899,321	363,276	-1,454,081	-1,569,293	-8,222,481
adjustments to reconcile net income to net cash from operating activities:
impairment loss	0	0
depreciation and amortization	7,894,000	7,836,000	7,558,000	7,469,000	7,449,000	6,911,000	6,723,000	6,404,000	6,134,000	5,786,000	5,480,000	5,365,000	5,303,000	5,157,000	4,950,000	4,837,000	7,369,913	830,377	844,281	824,429	825,051	792,916	496,690	300,565	264,746	214,000	191,359	187,834	184,075	176,354	131,551	100,770	97,847	72,904	72,298	48,353	45,673	42,712	50,040	50,046	55,140	53,401	79,199	90,331	121,902	95,029	83,160	78,891	69,182	66,599	56,761	52,935	15,009,280,496	38,623	31,363	31,502	21,807	15,923	14,631
amortization of debt discount	318,000	424,000	597,000	601,000	598,000	645,000	642,000	641,000	651,000	644,000	643,000	643,000	500,000	240,000	232,000	264,000	189,396	187,499			241,630	15,997	15,410	15,383																				0	0	8,843	57,558	70,372	136,289	135,271	128,916	121,565	64,173,457,416,569	1,068,978	2,181,878	1,555,691	681,523	540,311	418,275
non-cash operating lease expense	1,379,000	1,565,000	1,466,000	1,360,000	1,700,000	1,122,000	1,182,000	1,099,000
unrealized (gain) loss on investments in equity securities	2,344,000	-2,471,000	348,000	678,000	-3,563,000	2,360,000	1,405,000	-1,510,000
realized gain on available-for-sale investments														-8,000	45,000	40,000		6,940	-5,958	-10,934
gain on extinguishment of debt	0	-17,326,000
gain on divested business
stock-based compensation expense	4,413,000	4,838,000	4,997,000	5,456,000	5,848,000	5,976,000	5,800,000	5,184,000	5,333,000	5,366,000	5,258,000	4,125,000	4,182,000	4,148,000	4,025,000	2,990,000	2,561,454	2,432,671	2,301,497	1,620,378	1,610,357	1,945,775	1,991,755	1,413,735		1,498,663	1,445,729	1,049,510	964,857	794,559	770,442	799,797	749,196			637,635	480,377	316,486	210,768	187,358	167,094
loss on disposal of property and equipment	89,000	57,000	107,000	131,000	677,000	87,000	113,000	77,000	226,000	270,000	212,000	92,000	417,000	12,000	42,000	71,000	170,108	92,556	40,743	80,593		58,618	52,651	47,603	225,848	109,173	41,861	20,585	26,382	32,602	17,238	7,249	9,123	131,465	4,430
change in credit losses	-260,000	36,000	-117,000	99,000		-2,000	-30,000	-103,000
excess and obsolete inventory									105,000	0
change in contingent consideration	-518,000	412,000	-2,034,000	293,000	-685,000	-137,000	-114,000	46,000
changes in operating assets and liabilities:
accounts receivable	-3,074,000	-2,633,000	1,121,000	437,000	2,585,000	-16,000	2,518,000	-1,414,000	4,170,000	-4,016,000	-7,631,000	3,340,000	-706,000	-974,000	-377,000	-5,213,000	-1,867,710	-774,772	-929,195	954,677	398,999	-1,401,375	-1,929,567	-664,667	-318,907	389,630	-1,268,700	-760,428	-223,405	215,482	-272,370	-10,326	-1,691	-406,717	84,160	23,825	-171,077	-184,488	621	78,971	28,309	94,986	-248,018	-30,769	-25,602	1,358	-35,442	-20,151	-19,870	23,016	-26,124	48,220		-2,757	282	-5,009	-349	-2,422	19,360
inventories	536,000	284,000	1,319,000	1,113,000	3,080,000	-325,000	-2,486,000	1,239,000	-3,025,000	-1,703,000	-1,761,000	-7,715,000	-2,999,000	-1,842,000	-150,000	-988,000	1,324,661	61,754	-73,788	9,373	-123,041	-44,482	-79,348	-6,576	-90,215	-33,009	24,636	-7,130	-17,633	-1,661	18,539	1,353	-13,743	-55,197	26,350	-6,500	-35,124	-2,722	-8,154	-20,203	-8,898	305	13,297	460	-8,413	4,248	2,284	-739	15,639					0	63,327	17,685	-111,859	-226,309	-73,084
prepaid expenses and other current assets	-2,603,000	1,835,000	-207,000	-1,174,000	2,195,000	-3,549,000	1,522,000	-271,000	-179,000	-376,000	-1,064,000	21,000	334,000	3,234,000	6,033,000	-6,545,000	-7,671,519	-53,684	110,537	94,666	-140,850	-429,138	215,353	10,049				-25,035	44,586	12,490	-34,500
deposits	-1,638,000	204,000	0	-9,000	-11,000	-455,000	1,000	-198,000	-69,000	-18,000			1,000	-20,000	1,000	229,000	-53,549	-772	-51,678	-46,001	-30,613	683
operating lease liabilities	-1,059,000	-1,527,000	-1,452,000	-1,302,000	-1,586,000	-907,000	-1,098,000	-1,004,000
accounts payable and other accrued expenses	2,946,000	-728,000	-2,558,000	264,000	-2,730,000	2,838,000	402,000	-3,276,000	-3,311,000	1,111,000	-2,176,000	-2,107,000	1,936,000	2,649,000	-5,515,000	532,000	-2,120,123	3,215,353	3,084,458	65,312	-697,790	-444,381	1,053,313	659,335	-223,192	-333,521	856,444	105,343	-4,681	-123,881	329,514	72,321	-160,477	-37,317	453,243	144,813	-247,509	54,889	10,381	164,096	-20,228
accrued compensation and related expenses	2,044,000	438,000	-3,349,000	2,719,000	871,000	1,765,000	-1,714,000	1,962,000	-351,000	363,000	-3,722,000	2,141,000	1,277,000	1,906,000	-1,465,000	804,000	2,491,967	702,567	-819,287	767,753	336,566	32,897	-219,344	491,123	377,357	-18,026	-171,613	149,018	30,468	184,704	-5,413	-8,609	-131,910	168,733	10,191	-55,609	-285,460	108,076	67,977	47,644	47,727	62,850	49,011	23,677	16,577	-107,785	-121,719	128,667	149,729	18,447
deferred revenue	44,000	-246,000	-439,000	462,000	-299,000	653,000	-82,000	570,000	-110,000	-269,000	-121,000	-30,000	239,000	-151,000	-35,000	49,000	-178,108	-93,297	-10,878	-26,717	-55,734	201,761	-36,433	-28,397
net deferred tax liability	6,000			-551,000		30,000	-466,000	246,000
net cash from operating activities	-5,480,000	447,000	-8,025,000	-3,265,000	2,482,000	-1,959,000	-4,054,000	2,774,000	3,654,000	982,000	-7,011,000	524,000	2,614,000	8,876,000	2,627,000	-5,991,000	-9,713,157	-4,843,235	-1,368,968	1,059,360	741,021	-813,395	-1,061,883	-189,603	-359,406	-664,226	-1,265,095	-1,063,653	-965,015	-568,172	-829,923	-1,534,360	-1,449,933	-1,969,641	-1,393,693	-1,068,067	-1,874,289	-1,292,409	-1,060,711	-857,533	-917,049	-1,221,253	-841,575	-1,022,319	-1,231,052	-1,424,817	-1,644,687	-1,546,627	-1,172,205	-1,406,728	-985,026	-1,247,452		-796,196	-639,537	-505,960	-458,440	-889,108	-694,914
capex	-5,219,000	-4,239,000	-3,790,000	-4,006,000	-11,573,000	-8,969,000	-8,674,000	-9,569,000	-7,857,000	-5,190,000	-4,815,000	-4,245,000	-8,326,000	-8,851,000	-3,894,000	-2,811,000	-3,799,197	-2,576,652	-1,945,992	-596,159	-1,146,898	-1,610,798	-1,457,120	-1,121,025	-1,081,897	-863,049	-699,540	-269,543	-207,350	-391,239	-631,082	-67,340	-193,857	-405,258	-378,591	-225,787	-109,615	-2,279	0	0	0	655	-2,045	-24,386	-2,908	-43,871	-78,329	-44,477	-42,333	-27,988	-60,228	-210,851		0	0	0	0	0	0
free cash flows	-10,699,000	-3,792,000	-11,815,000	-7,271,000	-9,091,000	-10,928,000	-12,728,000	-6,795,000	-4,203,000	-4,208,000	-11,826,000	-3,721,000	-5,712,000	25,000	-1,267,000	-8,802,000	-13,512,354	-7,419,887	-3,314,960	463,201	-405,877	-2,424,193	-2,519,003	-1,310,628	-1,441,303	-1,527,275	-1,964,635	-1,333,196	-1,172,365	-959,411	-1,461,005	-1,601,700	-1,643,790	-2,374,899	-1,772,284	-1,293,854	-1,983,904	-1,294,688	-1,060,711	-857,533	-917,049	-1,220,598	-843,620	-1,046,705	-1,233,960	-1,468,688	-1,723,016	-1,591,104	-1,214,538	-1,434,716	-1,045,254	-1,458,303		-796,196	-639,537	-505,960	-458,440	-889,108	-694,914

cash flows from investing activities:
purchases of property and equipment	-5,219,000	-4,239,000	-3,790,000	-4,006,000	-11,573,000	-8,969,000	-8,674,000	-9,569,000	-7,857,000	-5,190,000	-4,815,000	-4,245,000	-8,326,000	-8,851,000	-3,894,000	-2,811,000	-3,799,197	-2,576,652	-1,945,992	-596,159	-1,146,898	-1,610,798	-1,457,120	-1,121,025	-1,081,897	-863,049	-699,540	-269,543	-207,350	-391,239	-631,082	-67,340	-193,857	-405,258	-378,591	-225,787	-109,615	-2,279	0			655	-2,045	-24,386	-2,908	-43,871	-78,329	-44,477	-42,333	-27,988	-60,228	-210,851
software development costs	-125,000	-687,000	-1,631,000	-443,000	-414,000	-2,296,000	-2,071,000	-463,000	-511,000	-401,000	-351,000	-213,000	-113,000	-308,000	-256,000	-193,000
purchases of short-term investments	0	-799,000	-35,884,000	-14,038,000					-8,435,000	-18,742,000	-106,257,000	-30,354,000	-190,427,000	-50,287,000	-26,675,000	-215,318,000	-22,442,805	-41,176	-120,056,684	-16,195,335	-151,034	-37,024,265	-1,010,199	-5,010,461	-8,228
proceeds from divested business
proceeds from related party loans
sales/maturities of short-term investments	9,138,000	159,753,000	54,975,000	25,250,000	47,500,000	30,000,000	44,637,000	7,850,000	24,023,000	23,075,000	48,760,000	36,000,000	3,000,000	33,000,000	5,000,000	3,000,000	6,956,756	122,997,378	3,000,000	16,278,866
patent and trademark costs	-297,000	-163,000	-349,000	-318,000	-255,000	-225,000	-214,000	-177,000	-96,000	-160,000	-220,000	-138,000	-105,000	-41,000	-61,000	-48,000	-83,704	-41,362	-45,080	-29,854	-25,138	-5,441	-22,541	-20,488	-12,398	-7,004	-11,822	-15,350
net cash from investing activities	3,479,000	153,570,000	13,321,000	6,445,000	-14,760,000	18,510,000	33,678,000	-1,383,000	7,124,000	-5,865,000	-63,990,000	3,050,000	-195,971,000	-27,008,000	-30,905,000	-215,370,000	-383,059,950	120,338,188	-119,047,756	-542,482	789,874	-36,645,504	-21,419,511	-5,651,974	-1,102,523	-10,785,444	-711,362	-284,893	-234,155	-405,768	-641,281	-72,340	-193,857	-405,258	-378,591	-225,787	-109,615	-2,279	0			655	-2,045	-24,386	-2,908	-43,871	-132,539	-69,814	-70,904	-49,525	-89,789	-255,232		3,884	-6,353	-27,786	54,560	-23,544	-30,132
cash flows from financing activities:
proceeds from exercise of stock options	2,142,000	21,000	9,000	618,000	-2,000	180,000	1,208,000	92,000		999,000
repurchase of common stock									-4,611,000	0	-25,000,000	-8,349,000
cash paid for repurchase of 2026 convertible senior notes
repayment of 2025 convertible senior notes
repayment of notes payable	-28,000	-41,000	-36,000	-36,000	-45,000	-15,000	-21,000	10,000		-1,430,000																								0	0	0	-741,377
repayment of finance lease liabilities	-102,000	-162,000	-74,000	-70,000	-79,000	-53,000	-39,000	-31,000	-36,000			-13,000	-16,000	-12,000	-14,000	-18,000	-18,289	-19,470	-17,942	-14,299	-5,930	-5,835	-5,748	-5,678
net cash from financing activities	2,012,000	-155,291,000	-8,764,000	512,000	-126,000	-24,891,000	1,148,000	71,000	-5,306,000	-459,000	-25,360,000	-8,049,000	288,575,000	2,491,000	1,883,000	271,393,000	266,443,311	2,150,581	114,127,553	2,863,555	1,092,665	1,410,416	70,356,768	1,290,420	24,936,013	5,301,128	2,993,600	5,300,351	3,742,156	-704,394	11,479,535	-360,992	3,376,984	-80,000	-40,000	5,967,644	2,964,637	1,925,952	1,731,290	858,222	717,973	1,370,209	531,121	-37,822	-67,973	-177,280	-325,924	-605,398	7,810,576	421,484	2,723,358	-30,000	6,372,359,235,214	318,862	1,209,726	840,910	-39,000	-58,000	683,713
effect of exchange rates on cash and cash equivalents	613,000	-519,000	263,000	-375,000	-723,000	499,000	-1,996,000	481,000		-968,000	-1,053,000	-178,000		-1,036,000	1,258,000	-1,411,000		15,511	-7,245	7,251		-8,576	-5,147	-3,982
net change in cash and cash equivalents	624,000	-1,793,000	-3,205,000	3,317,000	-13,127,000	-7,841,000	28,776,000	1,943,000	5,871,000	-6,310,000	-97,414,000	-4,653,000	95,421,000	-16,677,000	-25,137,000	48,621,000	-125,114,313	117,661,045	-6,296,416	3,387,684	2,649,616	-36,057,059	47,870,227	-4,555,139	23,477,481	-6,161,493	1,017,143	3,951,805	2,542,986	-1,678,334	10,008,331	-1,733,428.498	1,733,194	-2,454,899	-1,812,284	4,673,790	980,733	631,264					-312,499	-1,084,527	-1,301,933	-1,645,968	-2,103,150	-2,221,839	6,567,467	-1,034,769	1,648,543	-1,532,684	2,982,578	-473,450	563,836	307,164	-442,880	-970,652	-41,333
cash and cash equivalents — beginning of period	0	0	0	46,346,000	0	0	0	36,595,000		0	0	139,101,000		0	0	36,873,000		0	0	47,234,770		0	0	37,327,125		0	0	15,042,189	0	0	4,524,529	0	2,792,526		0	0	1,405,186		0	0	369,581
cash and cash equivalents — end of period	624,000	-1,793,000	-3,205,000	49,663,000	-13,127,000	-7,841,000	28,776,000	38,538,000		-6,310,000	-97,414,000	134,448,000		-16,677,000	-25,137,000	85,494,000		117,661,045	-6,296,416	50,622,454		-36,057,059	47,870,227	32,771,986		-6,161,493	1,017,143	18,993,994	2,542,986	-1,678,334	14,532,860	-1,967,692	4,525,720		-1,812,284	4,673,790	2,385,919		670,579	-67,162	170,505
reconciliation of cash and cash equivalents to the condensed consolidated balance sheets:
cash and cash equivalents from continuing operations
cash and cash equivalents from discontinued operations
total cash and cash equivalents — beginning of period
total cash and cash equivalents — end of period
supplemental disclosure of cash flow information:
cash paid for interest	2,064,000	-982,000	1,573,000	38,000	1,607,000	67,000
cash paid for income taxes	243,000	472,000	290,000	417,000	511,000	-152,000	670,000	433,000
supplemental disclosure of non-cash financing activities:
operating lease right-of-use assets and operating lease liabilities	19,446,000	1,357,000			1,528,000	3,978,000	1,167,000	4,436,000
net unrealized gain on available-for-sale debt securities	-359,000	1,964,000	994,000	261,000	3,666,000	624,000
reclassification of realized gain on available-for-sale debt securities to earnings	-400,000	-7,843,000	3,933,000	-2,314,000	-4,397,000											30,000	-15,800	-7,752	26,158	394	1,379	8,963	9,748	3,098
paid-in-kind preferred stock dividend, including beneficial conversion feature	2,000,000	2,000,000	2,000,000	2,000,000	2,000,000	2,000,000	2,000,000	2,000,000
fixed assets included in accounts payable and accrued liabilities	76,000	-437,000	-78,000	542,000	-130,000	-250,000	115,000	707,000	522,000	84,000	-152,000	549,000	-142,000	-2,314,000	3,670,000	198,000	172,154	-322,568	41,280	608,134	102,402
contingent consideration reclassed to accounts payable and accrued liabilities
purchase of equipment through finance lease obligation
realized loss on available-for-sale investments	102,000					-7,000				33,000	31,000	49,000
realized loss on investments in equity securities	0																285,228	0	11,597	793,175
gain on insurance settlement					0	0	0	-2,642,000	0
insurance proceeds for operations					0	0	0	1,212,000	3,454,000	118,000	3,311,000	3,000,000
insurance proceeds for loss of fixed assets					0	0	0	976,000	0	0	1,000,000	2,000,000
cash paid for acquisitions
cash paid for repurchase of 2026 senior notes					0
intangible assets included in property and equipment
acquisitions
cash paid to repurchase of 2026 senior notes		-155,109,000
realized (gain) loss on available-for-sale investments			448,000	-2,416,000				86,000
net deferred tax asset
goodwill impairment
realized loss on available-for-sale debt securities
(gain) loss on extinguishment of debt
change in expected credit losses
net deferred tax (asset) liability
proceeds from issuance of series c convertible preferred stock, net of issuance costs
proceeds from public offering, net of offering costs
proceeds from issuance of convertible senior notes																	0	0
purchase of equipment through finance lease obligations																	484	0
common stock issued for conversion of debt and accrued interest
receivable included in prepaid expenses and other current assets
common stock issued for cell&co acquisition										0
reclassification of realized loss on available-for-sale debt securities to earnings							-730,000	99,000		0	-79,000	33,000
net unrealized (gain) loss on available-for-sale debt securities								-3,675,000
loss on extinguishment of debt																																																									0	6,804,311.059	6,902.941
realized (gain) loss on available-for-sale debt securities
benefit from bad debt									221,000	-22,000	4,000	31,000	-237,000	48,000	152,000	63,000	133,021	30,003	30,000	3,976	0	43			-27,535	32,075			10,000			25,365	7,425	2,503	1,963			2,248	0
changes in operating assets and liabilities, net of effects of acquisition:
change in operating lease right-of-use assets and lease liabilities									253,000	289,000	22,000	5,000	259,000	83,000	160,000	60,000	72,938	47,577	6,499	6,986	3,238	5,439	-5,668	-9,309
proceeds from exercise of stock options and warrants												313,000	3,009,000	2,503,000	1,897,000	1,586,000	1,076,105	2,418,046	3,015,995	2,877,854	1,078,847	1,412,979	1,555,070	1,315,846	417,952	1,950,823	2,993,600	658,544						0	0	0	10,881	80,978	0	0	11,631	146,889
proceeds from issuance of common stock, net of issuance costs
repayment of note payable																																																									0	0	-12,000
payment of deferred financing costs																	495	-247,995				0	0	-19,748																				-5,822			-27,500	-130,770		-1,897				-73,180	-73,700	-55,590			-191,875
effect of exchange rate changes on cash and cash equivalents																									3,397
cash and cash equivalents — beginning of year
cash and cash equivalents — end of year
supplemental disclosure of non-cash investing and financing activities:
unrealized loss on investments in equity securities										3,880,000	3,648,000	4,908,000									13,824
contingent consideration
deferred tax (asset) liability										-488,000
mve net working capital settlement
acquisitions, net of cash acquired
proceeds from public offering, net of 17.7 million in offering costs														0	0	269,825,000
conversion of series c preferred stock to common stock														0	0	765,000
cost of series c preferred stock conversion included in additional paid-in-capital and accounts payable and accrued liabilities														0	0	1,800,000
cryopdp goodwill adjustment included in deferred tax liability														53,000	-517,000	1,394,000
cryopdp goodwill adjustment included in fixed assets														-1,000	0	71,000
fair value adjustment of ctsa contingent consideration included in goodwill and contingent consideration
note valuation adjustment included in notes payable and goodwill
net unrealized loss on available-for-sale securities										-6,538,000	-33,439,000	14,065,000
paid-in-kind preferred stock dividend										2,000,000	2,000,000	2,000,000
acquisition of cell&co
acquisition of ctsa and f-airgate														-21,000
repayment of capital lease obligation
mve estimated working capital adjustment included in goodwill and accounts payable
deferred tax liability												60,000		768,000	25,000	80,000		-9,002	27,008	9,002
mve goodwill adjustment included in fixed assets
note valuation adjustment included in note payable and goodwill														9,000	-991,000	1,266,000
interest expense on convertible note settled by issuance of common stock
accelerated stock-based compensation expense																					-1,227,890
unrealized gain on investments in equity securities														152,000	-107,000	263,000			-192,163	-144,415			-43,803	-31,545
proceeds from the issuance of convertible senior notes
fair value adjustment of ctsa contingent consideration included in goodwill and contingent consideration accrual
net unrealized (loss)/gain on available-for-sale securities														-366,000
reclassification of realized (loss)/gain on available-for-sale debt securities to earnings														28,000
purchase of equipment through capital lease obligations																				202,619
financing costs included in accounts payable and accrued liabilities
convertible debt costs included in accounts payable and accrued liabilities
net unrealized gain on available-for-sale securities																768,000			-135,178	470,924
unrealized (gain)/loss on investments in equity securities
cash paid for acquisition																					112,944	0
proceeds from june 2019 public offering, net of offering costs																						3,272
net unrealized gain/(loss) on available-for-sale securities
realized gain on treasury notes and bills																					-19,189	-32,573
warrant inducement and repricing expense																									0	0	0	899,410
property and equipment disposal costs
accrued interest																													0	0	-1,843	-2,006	9,018	6,027	0	-18,988	-1,186	21,524	10,466	7,854	18,110	22,674	8,961	10,364	10,744	-1,483	11,799	12,581	13,444	14,127	14,574	15,011	335,830,007,465	45,826	121,919	156,406	45,235	16,354	118,164
maturities of short-term investments																					2,000,000	1,995,000
proceeds from issuance of convertible debt																																										1,352,000	591,000
proceeds from issuance of common stock, net of costs
proceeds from tender offer, net of offering costs
proceeds from the atm, net of offering costs
leasehold improvements paid by tenant allowance
proceeds from february 2018 tender offer, net of offering costs																									0	0	0	4,641,807
proceeds from atm, net of offering costs
change in net unrealized loss on available-for-sale securities
change in net unrealized gain on available-for-sale securities																							28,740	30,872
maturity of short-term investment																								500,000
amortization of debt discount and deferred financing costs																																						220,152	38,140	0	1,110,013	138,267	25,267
unrealized loss on short-term equity securities
stock-based compensation expense to employees, directors and consultants																																		826,926
repayment of related-party notes payable																													0	-563,842	-92,379	-128,140	-98,831
deferred offering costs in connection with future warrant repricing included in accounts payable and prepaid expenses and other current assets
amortization of debt discounts and deferred financing costs																													0	0	6,130	6,266	6,197		65,435	65,435	286,133
prepaid expenses and other assets																										-379,524																										1,915		-36,210	25,993	3,650	40,727	59,465	29,001
proceeds from the public offering, net of offering costs
supplemental disclosure of non-cash investing activities:
unrealized loss on available-for-sale securities
reduction of accounts payable for returned fixed assets
offering costs included in additional paid-in capital and accounts payable and other accrued expenses																															165,990
patent costs
proceeds from the april 2016 tender offer, net of offering costs
proceeds from the rights offering, net of offering costs																																-186,652	1,185,368
proceeds from the october 2016 tender offer, net of offering costs
cumulative undeclared preferred dividends recorded upon conversion of class a convertible preferred stock and class b convertible preferred stock into common stock
estimated relative fair value of warrants issued in connection with related-party notes payable
leasehold improvements paid by tenant allowance included in accounts payable and accrued expenses
reclassification of shipper inventory to property and equipment
warrant repricing expense																																0	1,929,818
trademark costs																													-26,805	-14,529	-10,199
proceeds from the common stock offering, net of offering costs																													0	-165,990	11,571,914
proceeds from april 2016 tender offer, net of offering costs
proceeds from exercise of stock options and warrants, net of costs
cumulative undeclared preferred dividends recorded upon conversion of class a convertible preferred stock and class b convertible preferred stock into common
reclassification of shipper inventory to fixed assets																																			0
leasehold improvements paid by tenant allowance included in accounts payable and other accrued expenses
issuance of common stock for accrued board of director compensation																																		0	0
estimated fair value of the beneficial conversion feature on related-party notes payable
other assets																																-342,072	-16,022			-66,144	-25,192	55,196	-37,101	5,467	-13,388
acquisition of intangible
proceeds from the tender offer, net of offering costs																																-46,200	2,290,447
proceeds from issuance of common stock and warrants in public offering, net of offering costs																																			0
proceeds from the issuance of class a and class b convertible preferred stock, net of offering costs
offering costs in connection with the rights offering included in accounts payable and other accrued expenses
purchase of fixed assets included in accounts payable and other accrued expenses
accretion of convertible preferred stock beneficial conversion feature and relative fair value of warrants issued in connection with the convertible preferred stock units to accumulated deficit																																		0	0	0	4,474,348	1,902,569	492,910	1,727,027	741,786
payment for deferred offering costs																																					-89,545
offering costs in connection with tender offer included in accounts payable and other accrued expenses																																	46,200
offering costs in connection with rights offering included in accounts payable and other accrued expenses																																	184,690
offering costs for future financing included in prepaid expenses and other current assets and accounts payable and other accrued expenses																																	24,204
deferred offering costs in connection with secondary public offering included in accounts payable and other accrued expenses
estimated relative fair value of beneficial conversion feature on related-party notes payable
loss on write-off of patents																																		0
proceeds from the issuance of notes payable
repayment of convertible debt
repayment of offering and deferred financing costs
estimated relative fair value of warrants issued in connection with notes payable																																						146,257
conversion of convertible debentures payable and accrued interest into convertible preferred stock units																																						0	0	0	1,766,997
estimated fair value of the beneficial conversion feature on related party notes payable
deposits and other current assets
proceeds from the issuance of preferred stock, net of offering costs																																			0	0	3,896,678		1,140,290	882,222	780,342
repayment of convertible debentures																																							0	0	-50,000
repayment of related party notes payable																																			-40,000	-60,000	-112,000		-24,000	-24,000	-24,000
offering costs in connection with convertible preferred stock included in accounts payable																																							0	0	9,658
fair value of common stock issued to consultant for future services included in other current assets
loss on disposal of cryogenic shippers																																						10,650	3,909	179	1,685	10,182	3,075	0					3,007	0	897	2,613	13,674
benefit from (recovery of) bad debt																																					3,340
deferred offering costs in connection with secondary public offering included in accounts payable																																					51,153
change in fair value of derivative instruments																																										-3	-1,196	6,112	-14,489	-19,335	-14,685	-34,283	227,270	-33,987	-126,345	-116,528
debt conversion expense																																										0	552,750
deferred financing costs in connection with convertible debt payable included in accounts payable
estimated relative fair value of warrants issued in connection with convertible bridge notes payable
estimated relative fair value of warrants issued in connection with related-party convertible notes payable
conversion of bridge notes payable and accrued interest into common stock units
proceeds from issuance of notes payable
proceeds from issuance of convertible debentures
repayment of offering and deferred costs
estimated relative fair value of warrants issued in connection with convertible debentures payable
conversion of bridge notes payable and accrued interest into shares of common stock and warrants																																											150,027
net decrease in cash and cash equivalents																																								-67,162	-199,076
deferred financing costs in connection with convertible debentures payable included in accounts payable
recovery of bad debt																																									-5,349
loss on write-off of intangible assets
reserve for bad debt
purchases of intangible assets																																															-54,210	-25,337	-28,571	-21,537				0
offering costs in connection with equity financing included in accounts payable																																												-5,822
release of restricted cash for repayment of convertible debentures
cash flows from operating activities
fair value of stock options and warrants issued to employees, directors and consultants																																											178,746
other current assets																																											-13,271	-18,400	-1,045	28,385	60,893	64,448
accounts payable and accrued expenses																																											350,935	223,125	47,406	30,894	142,752	35,998	50,524
cash flows from investing activities
cash flows from financing activities
repayments of convertible debt
payments of offering and deferred financing costs																																											-115,880
repayments of related party notes payable																																											-24,000	-32,000	-24,000	-16,000	-24,000	-30,000						-20,000	-30,000	-30,000	-30,000	-30,000	-30,000
cash and cash equivalents, beginning of period																																											0	0	0	4,617,535	0	9,278,443						0	0	249,758	0	0	2,231,031
cash and cash equivalents, end of period																																											-312,499	-1,084,527	-1,301,933	2,971,567	-2,103,150	7,056,604						-473,450	563,836	556,922	-442,880	-970,652	2,189,698
supplemental disclosure of cash flow information
cash paid during the period for:
interest																																												0	3,099	12,577	38,413	50,345	22,727	1,741	12,967	2,133
income taxes																																												0			0	1,600	0	0	0	1,600
release of restricted cash for repayment of convertible debentures payable																																												0	0	251,368
estimated relative fair value of warrants issued in connection with convertible debt payable
operating activities
interest accrued on restricted cash																																															-126	-148	-145	-166	-228	-226
investing activities
financing activities
repayments of convertible debentures payable																																												0	0	-82,800	-600,000	-576,628
proceeds from exercise of warrants																																															324,133	132,000
payment on line of credit
proceeds from release of restricted cash
supplemental disclosure of non-cash activities:
cashless exercise of warrants
fair value of stock options and warrants issued to consultants, employees and directors																																													168,190	80,836	198,949	171,591				152,067				272,312
payment of financing costs																																														-78,480											0
cash paid during the year for:
fair value of warrants issued to convertible debenture holders
proceeds from issuance of common stock, net of cash paid for issuance costs																																																	8,090,745
repayment of convertible debentures payable
repayment of deferred financing costs
restricted cash – convertible debenture holder escrow account funds
proceeds from exercise of options and warrants																																																					14,369,566,207	437,500			0	0	3,308
cash and cash equivalents, beginning of year																																																			0	3,629,886
cash and cash equivalents, end of year																																																			1,648,543	2,097,202
proceeds from private placement of common stock, net of cash paid for issuance costs
restricted cash-investor funds
deposits from investors
amortization of deferred financing costs																																																					15,951,560,528	56,177	17,675	7,904	10,766	10,767	17,162
fair value of stock issued to consultants
share-based compensation related to stock options and warrants issued to consultants, employees and directors																																																	86,305	51,871
loss on sale of assets																																																					8,387	0	0	797
accrued warranty costs																																																						0			0	0	-5,625
decrease in restricted cash																																																					10,000,096,759
proceeds from borrowings under convertible notes																																																					13,214,999,801,000	0
repayments of note payable to officer																																																						0			-6,000	-18,000	-18,000
payment of fees associated with the exercise of warrants
payment of related party notes payable																																																		-30,000	-30,000	-30,000
payment of fees associated with exercise of warrants																																																						-25,458
stock issued to consultants																																																					166,094,083,008	47,287	12,000	106,807	63,100	77,170	28,500
accounts payable																																																			120,908	-205,513	179,451	-54,265	72,375	102,893	83,131	12,974	1,561
inventory
accrued compensation and related expense																																																				9,293
purchases of intangibles																																																				-44,381
accrued expenses																																																						-97,436	112,278	93	-338	-9,643	9,398
repayment of line of credit
offering costs in connection with equity financing
deferred financing costs in connection with convertible debt financing and debt modifications
warrants issued as deferred financing costs in connection with convertible debt financing
purchase of intangible assets with warrants
debt discount in connection with convertible debt financing
conversion of debt and accrued interest to common stock
reclassification of embedded conversion feature to equity upon conversion
cashless exercise of warrants and stock options
cancellation of shares issued for debt principal reduction
change in fair value of warrants issued in connection of debt modification
cumulative effect of accounting change to debt discount for derivative liabilities
cumulative effect of accounting change to accumulated deficit for derivative liabilities
cumulative effect of accounting change to additional paid-in capital for derivative liabilities
reclassification of inventory to property and equipment
fair value of shares issued in connection with debt modifications
addition of principal due to debt modifications
reclassification of derivative liabilities to additional paid in capital upon effectively fixing conversion feature and warrant price
fair value of warrants and options issued to employees and directors
fair value of warrants issued to consultants
change in fair value of derivative instrument																																																						-4,508,352	4,535,848	-3,134,298
interest earned on restricted cash																																																						0	-465	-597		-2,276	-2,250
accrued salaries and related																																																						-17,897	23,622	14,928	67,538	-3,871	-4,354
purchases of fixed assets																																																						-8,201	-1	-9,766	-5,235	-23,544	-29,499
repayment of convertible notes																																																									0	0	-117,720
repayment of borrowings on line of credit																																																									-3,000	-10,000	-12,500
fair value of warrants issued to employees and directors																																																									-168,244
payment of trademark costs																																																								-18,020		0	-633
net proceeds from borrowings under convertible notes																																																								926,500	0	0	1,062,500
decrease (increase) in restricted cash
net proceeds from borrowings under line of credit
proceeds from issuance of common stock
fair value of stock options and warrants issued to employees and directors																																																											53,887

We provide you with 20 years of cash flow statements for Cryoport stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Cryoport stock. Explore the full financial landscape of Cryoport stock with our expertly curated income statements.

The information provided in this report about Cryoport stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.